跳至主要内容
临床试验/NCT05406661
NCT05406661尚未招募不适用

Registry of Local Recurrences After Breast-conserving Surgery in Portugal and Spain

Universidade do Porto0 个研究点目标入组 3,000 人开始时间: 2023年12月1日最近更新:
适应症

试验速览

阶段
不适用
状态
尚未招募
入组人数
3,000
主要终点
Determine prevalence of local recorrence of breast cancer after conserving surgery in Portugal and Spain

研究概览

简要总结

The ReLoCC project is a prospective, multicenter, clinical study to register cases of local recurrence after breast-conserving surgery, in centers dedicated to the treatment of breast cancer, in Portugal and Spain.

The comparison of the results obtained will allow the optimization of the treatment, making it increasingly personalized.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
Female
接受健康志愿者

入选标准

  • Female patients
  • Age > 18 years
  • Patients who have previously undergone breast-conserving surgery as part of the treatment of invasive or non-invasive (in situ) breast cancer
  • and adjuvant breast RT: total (WBI) or partial (PBI)
  • without adjuvant radiotherapy to the breast
  • Recent histological diagnosis of homolateral, invasive or non-invasive (in situ) breast carcinoma

排除标准

  • Age < 18 years
  • Stage 4 at diagnosis
  • Patients operated outside the participating Centers and for whom it is not possible to obtain complete information regarding the primary treatment
  • History of other primary invasive malignant tumor (except non-melanoma skin carcinomas)
  • Patients already treated for another local recurrence of breast carcinoma
  • Absence of clinical follow-up and records in clinical process

结局指标

主要结局

Determine prevalence of local recorrence of breast cancer after conserving surgery in Portugal and Spain

时间窗: 2 years

Number of cases per year

Follow-up of recurrences up to 5 years after treatment of first recurrence

时间窗: 5 years

Number of cases per year

次要结局

  • Determination of surgical morbidity of relapse treatment in follow up(From date of treatment until 30 days after treatment)
  • Assessment of patient quality of life(First and second year after treatment)
  • Identification of risk factors for local recurrence(On inclusion time (2 years))
  • Identification of predictive and response factors(On inclusion time (2 years))

研究者

申办方类型
Other
责任方
Sponsor

相似试验